| Old Articles: <Older 6741-6750 Newer> |
|---|
 |
The Motley Fool
October 4, 2010
Seth Jayson |
Does This Mean Volcano Will Bomb Next Quarter? Look at accounts receivable and days sales outstanding for a clue on Volcano's future.   |
The Motley Fool
October 4, 2010
Brian Orelli |
That's No Way to Make Friends Sanofi goes hostile on Genzyme. |
The Motley Fool
October 4, 2010
Seth Jayson |
Does This Mean Celgene Will Bomb Next Quarter? Is Celgene sending any potential warning signs? |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
IEEE Spectrum
October 2010
Michael Dumiak |
Nenad Filipovic's Coronary Calculus The Serbian engineer's equations model blood flow and could predict heart attacks |
The Motley Fool
September 30, 2010
Brian Orelli |
Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
September 29, 2010
Brian Orelli |
Boston Scientific: Strengths, Weaknesses, Opportunities, Threats One of the best ways to develop a picture of any company is with the SWOT analysis -- a look at a company's strengths, weaknesses, opportunities, and threats. Let's take a look at Boston Scientific in this light as it tries to turn itself around. |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
| <Older 6741-6750 Newer> Return to current articles. |
